PrimeVax Immuno-Oncology Revenue

Biotechnology Research • 400 Cypress Ave, South San Francisco, United States • 1-10 Employees

PrimeVax Immuno-Oncology revenue & valuation

Annual revenue	$598,885
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$2,000,000
Total funding	No funding

Key Contact at PrimeVax Immuno-Oncology

Bruce Lyday

Director Of Drug Development

Company overview

Headquarters	400 Cypress Ave, South San Francisco, California 94080, US
Website	primevax.com
NAICS	541714
SIC	873
Founded	2015
Employees	1-10
Socials

About PrimeVax Immuno-Oncology

PrimeVax Immuno-Oncology, Inc. is developing the only one-time, one-week cancer treatment. We use a combination of the dengue fever virus and autologous dendritic cells to induce a strong immune response along with personalized tumor targeting.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Director

Funding Data

PrimeVax Immuno-Oncology has never raised funding before.

PrimeVax Immuno-Oncology Tech Stack

Discover the technologies and tools that power PrimeVax Immuno-Oncology's digital infrastructure, from frameworks to analytics platforms.

Google Workspace

Modernizr

JavaScript libraries

Emotion

Development

Lodash

JavaScript libraries

reCAPTCHA

Security

Squarespace Commerce

Ecommerce

Stimulus

JavaScript frameworks

HSTS

Security

Open Graph

Miscellaneous

core-js

JavaScript libraries

Cart Functionality

Ecommerce

YUI

JavaScript libraries

Frequently asked questions

PrimeVax Immuno-Oncology is located in 400 Cypress Ave, South San Francisco, US.

PrimeVax Immuno-Oncology generates an estimated annual revenue of $598,885. This revenue figure reflects the company's market position and business performance in its industry.

PrimeVax Immuno-Oncology has an estimated valuation of $2,000,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

PrimeVax Immuno-Oncology was founded in 2015, making it 11 years old. The company has established itself as a significant player in its industry over this time.

PrimeVax Immuno-Oncology has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at PrimeVax Immuno-Oncology

Bruce Lyday

Director Of Drug Development

4.8

40,000 users